Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday morning, MarketBeat.com reports. The brokerage issued a sell rating and a $80.00 price objective on the biotechnology company’s stock.

Several other research analysts have also commented on SRPT. Evercore ISI decreased their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Raymond James reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a report on Thursday, October 10th. UBS Group boosted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $176.73.

Sarepta Therapeutics Trading Up 0.4 %

NASDAQ SRPT opened at $114.65 on Monday. Sarepta Therapeutics has a one year low of $78.67 and a one year high of $173.25. The company has a 50-day simple moving average of $121.80 and a 200-day simple moving average of $131.40. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market capitalization of $10.95 billion, a PE ratio of 91.72 and a beta of 0.81.

Insider Activity

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. grew its position in Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. CIBC Asset Management Inc grew its position in Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 86 shares in the last quarter. EP Wealth Advisors LLC grew its position in Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in Sarepta Therapeutics by 1.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after acquiring an additional 145 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.